WINT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.33%

Insider Buying (Last 12 Months): $4,914.00

Insider Selling (Last 12 Months): $0.00

Windtree Therapeutics Insider Trading History Chart

Windtree Therapeutics Share Price & Price History

^$1.56

▼ -0.08 (-4.88%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

Windtree Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2024	Craig Fraser	CEO	Buy	108	$45.50	$4,914.00	172
9/26/2023	Craig Fraser	CEO	Buy	2	$810.00	$1,620.00	61
4/25/2023	Craig Fraser	CEO	Buy	1	$1,701.00	$1,701.00	6
7/26/2022	Craig Fraser	CEO	Buy	0	$33,300.00	$0.00	2
7/26/2022	John P Hamill	CFO	Buy	0	$33,300.00	$0.00
6/29/2022	Craig Fraser	CEO	Buy	0	$37,800.00	$0.00	2

SEC Filings (Institutional Ownership Changes) for Windtree Therapeutics (NASDAQ:WINT)

29.33% of Windtree Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Windtree Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2025	Renaissance Technologies LLC	119,266	$42K	0.0%	N/A	1.079%
8/7/2023	Acadian Asset Management LLC	31,583	$39K	0.0%	N/A	0.613%
7/27/2023	Virtu Financial LLC	42,667	$54K	0.0%	N/A	0.828%
11/7/2022	Virtu Financial LLC	100,808	$30K	0.0%	+559.5%	0.329%
10/13/2022	PVG Asset Management Corp	187,060	$56K	0.2%	N/A	0.611%
11/12/2021	Renaissance Technologies LLC	187,400	$0.39M	0.0%	+28.6%	0.702%
11/10/2021	Skandinaviska Enskilda Banken AB publ	110,500	$0.23M	0.0%	+15.7%	0.414%
11/9/2021	BlackRock Inc.	49,708	$0.10M	0.0%	-13.6%	0.186%
8/16/2021	State Street Corp	19,300	$44K	0.0%	N/A	0.072%
8/16/2021	Frontier Wealth Management LLC	60,000	$0.14M	0.0%	N/A	0.225%
8/16/2021	Goldman Sachs Group Inc.	66,952	$0.15M	0.0%	N/A	0.251%
8/13/2021	Renaissance Technologies LLC	145,700	$0.33M	0.0%	+1,156.0%	0.546%
8/13/2021	Northern Trust Corp	65,380	$0.15M	0.0%	+28.8%	0.245%
8/13/2021	Geode Capital Management LLC	69,082	$0.16M	0.0%	N/A	0.259%
8/13/2021	Vanguard Group Inc.	626,057	$1.43M	0.0%	+16.1%	2.344%
8/10/2021	Skandinaviska Enskilda Banken AB publ	95,500	$0.22M	0.0%	N/A	0.364%
5/21/2021	Citadel Advisors LLC	66,035	$0.16M	0.0%	N/A	0.251%
5/18/2021	Citadel Advisors LLC	66,035	$0.16M	0.0%	N/A	0.251%
5/17/2021	HRT Financial LP	23,365	$57K	0.0%	N/A	0.089%
5/14/2021	PVG Asset Management Corp	63,795	$0.16M	0.5%	N/A	0.243%
5/13/2021	Renaissance Technologies LLC	11,600	$28K	0.0%	N/A	0.044%
5/13/2021	Kepos Capital LP	165,000	$0.40M	0.0%	+83.3%	0.628%
5/12/2021	Northern Trust Corp	50,743	$0.13M	0.0%	-29.9%	0.193%
5/4/2021	Envestnet Asset Management Inc.	36,334	$89K	0.0%	N/A	0.138%
3/9/2021	tru Independence LLC	60,000	$0.31M	0.0%	N/A	0.355%
2/16/2021	Paloma Partners Management Co	18,469	$95K	0.0%	-50.2%	0.109%
2/11/2021	Northern Trust Corp	72,385	$0.37M	0.0%	-11.3%	0.428%

Data available starting January 2016

See Full Table

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Today's Range

Now: $1.56

$1.45

$1.70

50 Day Range

MA: $4.74

$1.48

$11.00

52 Week Range

Now: $1.56

$1.45

$737.44

Volume

334,561 shs

Average Volume

706,845 shs

Market Capitalization

$1.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Who are the company insiders with the largest holdings of Windtree Therapeutics?: Windtree Therapeutics' top insider investors include:
Craig Fraser (CEO)
Learn More about top insider investors at Windtree Therapeutics.
Who are the major institutional investors of Windtree Therapeutics?: Windtree Therapeutics' top institutional investors include:
Renaissance Technologies LLC — 1.08%
Learn More about top institutional investors of Windtree Therapeutics stock.
Which major investors are buying Windtree Therapeutics stock?: Within the last quarter, WINT stock was bought by institutional investors including:
Renaissance Technologies LLC